Minerva Neurosciences IncNERV
Price$3.23

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Dec 2025
Net Income -$293.4M-20,492.7% YoYTTM through 31 Dec 2025
Free Cash Flow -$13.5MTTM through 31 Dec 2025

Margins

Current

Returns

208.5%ROE

Balance Sheet Health

Debt / Equity0.00x
Net Debt-$82.3Mnet cash position
Cash & Equivalents$82.3M

Quality Metrics

Earnings-Beat Rate33.3%

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Pharmaceutical Preparations$0
View details

Initiated global confirmatory Phase 3 clinical trial (C19 trial) in Q2 2026 with topline efficacy data expected in 2H 2027.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.